A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome

NCT02722798 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome

Interventions

DRUG: KRN23

Sponsor

Kyowa Kirin Co., Ltd.